Cargando…

Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors

BACKGROUND: Immunotherapy is a new paradigm for the treatment of non‐small‐cell lung cancer (NSCLC), and targeting the PD‐1 or PD‐L1 pathway is a promising therapeutic option. Although PD‐1/PD‐L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to active...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Da Hyun, Chung, Chaeuk, Kim, Ju‐Ock, Jung, Sung Soo, Park, Hee Sun, Park, Dong Il, Jung, Sun Young, Park, Myoungrin, Lee, Jeong Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209802/ https://www.ncbi.nlm.nih.gov/pubmed/30253080 http://dx.doi.org/10.1111/1759-7714.12877

Ejemplares similares

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2021)

Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2020)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2021)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
por: Shi, Wei, et al.
Publicado: (2023)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer
por: Hong, Green, et al.
Publicado: (2022)

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
por: Baxi, Shrujal, et al.
Publicado: (2018)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
por: Zhang, You-Cheng, et al.
Publicado: (2023)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
por: Zhu, Xinxin, et al.
Publicado: (2017)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

OR28-07 Increased BMI Is Associated With Anti PD-1/PD-L1-Induced Thyroid Immune-Related Adverse Events
por: Pollack, Rena, et al.
Publicado: (2020)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2022)

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study
por: Zheng, Xiaowei, et al.
Publicado: (2022)

Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review)
por: Sun, Guangshun, et al.
Publicado: (2022)

Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis
por: Sun, Xiaoying, et al.
Publicado: (2017)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
por: Griewing, Luisa Maria, et al.
Publicado: (2021)

Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models
por: Kim, Woorim, et al.
Publicado: (2021)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors
por: Wang, Zhiyi, et al.
Publicado: (2023)

Dynamic changes in pathology and PD‐L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report
por: Hong, Green, et al.
Publicado: (2023)

Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer
por: Yun, Tian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4a6f2r14844q02edfg7lgcfk0